SCHEMBL2385197

SCHEMBL2385197

CCc1ccc(F)c(NC(=O)N2CCN(c3ccccc3OCc3ccnc(N)n3)CC2)c1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.49
MAPK1 P28482 3/20 0.45
L3MBTL1 Q9Y468 3/20 0.45
KMT2A Q03164 5/20 0.44
MEN1 O00255 4/20 0.44
KDM4E B2RXH2 3/20 0.43
NPSR1 Q6W5P4 2/20 0.43
HTT P42858 1/20 0.43
TRPV1 Q8NER1 2/20 0.41
RBP4 P02753 1/20 0.41
PKM P14618 1/20 0.41
NPC1 O15118 1/20 0.40
USP2 O75604 1/20 0.40
ALDH1A1 P00352 1/20 0.40
TSHR P16473 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PANK3 Q9H999 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2384857 0.90 MEN1 (0.43) MAPTMAPK1KMT2AMEN1KDM4E
SCHEMBL2383530 0.87 MAPT (0.45) MAPTMAPK1L3MBTL1KMT2AMEN1
SCHEMBL2384230 0.86 MAPT (0.55) MAPTMAPK1L3MBTL1KMT2AMEN1
SCHEMBL2384332 0.86 MAPT (0.50) MAPTMAPK1L3MBTL1KMT2AMEN1
SCHEMBL2385658 0.85 RBP4 (0.40) MAPTMAPK1KDM4ENPSR1TRPV1
SCHEMBL2386446 0.85 ALDH1A1 (0.38) MAPTMAPK1KMT2AMEN1NPSR1
SCHEMBL2385379 0.84 TRPV1 (0.38) MAPTMAPK1L3MBTL1KMT2AMEN1
SCHEMBL2385918 0.84 MAPT (0.55) MAPTMAPK1L3MBTL1KMT2AMEN1
SCHEMBL2384340 0.84 MAPT (0.45) MAPTMAPK1L3MBTL1KMT2AMEN1
SCHEMBL2385620 0.81 MAPT (0.51) MAPTMAPK1L3MBTL1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US claimed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275952-A1 Tie-2 Modulators and Methods of Use TIE1, TEK, KDR MAPT 2716/4885MAPK1 263/4885L3MBTL1 3061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.